Drug Search Results
More Filters [+]

HRS-5041

Alternative Names: HRS-5041, HRS 5041, HRS5041
Latest Update: 2024-10-16
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Jiangsu Hengrui Medicine Co
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for HRS-5041

Countries in Clinic: Australia, China

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Prostate Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

HRS-5041-201

P2

Recruiting

Prostate Cancer

2025-09-01

HRS-5041-101

P1

Recruiting

Prostate Cancer

2025-08-31

39%

HRS-5041-102

P1

Recruiting

Prostate Cancer

2024-12-03

Recent News Events

Date

Type

Title